
Pride 2023: Does your company have LGBTQ+-inclusive health care? (Viewpoint)
Offering LGBTQIA+ inclusive health care benefits is just smart business. Click here to view original post Click here to view original post
Offering LGBTQIA+ inclusive health care benefits is just smart business. Click here to view original post Click here to view original post
The companies still face at least one more hurdle before they can finalize the deal. Click here to view original post Click here to view original post
Chief Executive Francis deSouza comfortably survived Icahn’s attempt to oust him from the board, but the company’s ‘say on pay’ proposal was overwhelmingly rejected by shareholders Click here to view original post Click here to […]
If you earn $100,000 in salary, your annual tax under the new Washington CARES Act payroll tax will be $580 per year. Click here to view original post Click here to view original post
InnerTrek already offers psilocybin facilitator training in Damascus, Oregon. Click here to view original post Click here to view original post
SAN DIEGO, June 1, 2023 /PRNewswire/ — Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. […]
~Jaime Herrera Beutler of Clark County, Washington joins the fight against kidney disease ~ NEW YORK, June 1, 2023 /PRNewswire/ — The National Kidney Foundation (NKF) is excited to announce the appointment of Jaime Herrera […]
In Amgen’s new oncology video series, patient Gina calls her colorectal cancer diagnosis “the best worst thing that’s ever happened to me.” She goes on to talk about her stage-four diagnosis and initial, terminal prognosis […]
Published findings demonstrate PrimateAI-3D’s ability to improve genetic risk prediction and drug target discovery using primate DNA and advanced artificial intelligence SAN DIEGO, June 1, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader […]
Encouraging antitumor activity in heavily pretreated population during dose finding Well tolerated across broad dose range in phase 1 first-in-human study Poster Presentation at ASCO on June 3, 8:00-11:00 a.m. CT LOS ANGELES, June 1, […]
© 2022 Biotech Networks, LLC